KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival, especially those with pathological complete response (pCR). The response to NAC according to molecular subtypes has been discussed. Molec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jütte, Hendrik Jan (VerfasserIn) , Reike, Moritz (VerfasserIn) , Wirtz, Ralph M. (VerfasserIn) , Kriegmair, Maximilian (VerfasserIn) , Erben, Philipp (VerfasserIn) , Tully, Karl (VerfasserIn) , Weyerer, Veronika (VerfasserIn) , Eckstein, Markus (VerfasserIn) , Hartmann, Arndt (VerfasserIn) , Eidt, Sebastian (VerfasserIn) , Wezel, Felix (VerfasserIn) , Bolenz, Christian (VerfasserIn) , Tannapfel, Andrea (VerfasserIn) , Noldus, Joachim (VerfasserIn) , Roghmann, Florian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 26 May 2021
In: Journal of Personalized Medicine
Year: 2021, Jahrgang: 11, Heft: 6, Pages: 1-13
ISSN:2075-4426
DOI:10.3390/jpm11060473
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/jpm11060473
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2075-4426/11/6/473
Volltext
Verfasserangaben:Hendrik Jütte, Moritz Reike, Ralph M. Wirtz, Maximilian Kriegmair, Philipp Erben, Karl Tully, Veronika Weyerer, Markus Eckstein, Arndt Hartmann, Sebastian Eidt, Felix Wezel, Christian Bolenz, Andrea Tannapfel, Joachim Noldus and Florian Roghmann

MARC

LEADER 00000caa a2200000 c 4500
001 1772422061
003 DE-627
005 20230427055854.0
007 cr uuu---uuuuu
008 211005s2021 xx |||||o 00| ||eng c
024 7 |a 10.3390/jpm11060473  |2 doi 
035 |a (DE-627)1772422061 
035 |a (DE-599)KXP1772422061 
035 |a (OCoLC)1341421594 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Jütte, Hendrik Jan  |d 1984-  |e VerfasserIn  |0 (DE-588)1051447860  |0 (DE-627)786302275  |0 (DE-576)406526001  |4 aut 
245 1 0 |a KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer  |c Hendrik Jütte, Moritz Reike, Ralph M. Wirtz, Maximilian Kriegmair, Philipp Erben, Karl Tully, Veronika Weyerer, Markus Eckstein, Arndt Hartmann, Sebastian Eidt, Felix Wezel, Christian Bolenz, Andrea Tannapfel, Joachim Noldus and Florian Roghmann 
264 1 |c 26 May 2021 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.10.2021 
520 |a Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival, especially those with pathological complete response (pCR). The response to NAC according to molecular subtypes has been discussed. Molecular targets such as estrogen receptor (ESR1) and human epidermal growth factor receptor 2 (ERBB2) play an important role in breast cancer management and have also been associated with urothelial bladder cancer. Hence, the association of Keratin 20 (KRT20) Keratin 5 (KRT5), ESR1, and ERBB2 mRNA expression in MIBC at transurethral resection (TUR-BT) with pCR after NAC was analyzed retrospectively. Formalin-fixed paraffin-embedded tumour tissue samples from TUR-BT of 54 patients (42 males, 12 females, median age of 64) with MIBC were analyzed for KRT20, KRT5, ESR1, and ERBB2 mRNA expression. After NAC, RC was performed, and the specimens were evaluated for pCR. Statistical analyses comprised nonparametric and chi2 testing, partition models, and Spearman correlation analyses. After NAC, 22 out of 54 patients (40.7%) had pCR. Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009). Elevated ERBB2 expression was positively correlated with luminal expression features such as KRT20, and negatively with basal characteristics such as KRT5. Patients with MIBC showing a high expression of ERBB2, ESR1, or KRT20 have a significantly higher chance of pCR following NAC. These findings might improve patient selection for NAC in MIBC. 
650 4 |a bladder cancer 
650 4 |a chemotherapy 
650 4 |a muscle invasive 
650 4 |a risk stratification 
650 4 |a subtype 
700 1 |a Reike, Moritz  |e VerfasserIn  |4 aut 
700 1 |a Wirtz, Ralph M.  |e VerfasserIn  |4 aut 
700 1 |a Kriegmair, Maximilian  |d 1987-  |e VerfasserIn  |0 (DE-588)1049742745  |0 (DE-627)782573347  |0 (DE-576)403726840  |4 aut 
700 1 |a Erben, Philipp  |d 1973-  |e VerfasserIn  |0 (DE-588)128501014  |0 (DE-627)373920997  |0 (DE-576)297181661  |4 aut 
700 1 |a Tully, Karl  |e VerfasserIn  |4 aut 
700 1 |a Weyerer, Veronika  |e VerfasserIn  |4 aut 
700 1 |a Eckstein, Markus  |e VerfasserIn  |4 aut 
700 1 |a Hartmann, Arndt  |e VerfasserIn  |4 aut 
700 1 |a Eidt, Sebastian  |e VerfasserIn  |4 aut 
700 1 |a Wezel, Felix  |e VerfasserIn  |4 aut 
700 1 |a Bolenz, Christian  |e VerfasserIn  |4 aut 
700 1 |a Tannapfel, Andrea  |e VerfasserIn  |4 aut 
700 1 |a Noldus, Joachim  |e VerfasserIn  |4 aut 
700 1 |a Roghmann, Florian  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of Personalized Medicine  |d Basel : MDPI, 2011  |g 11(2021), 6, Artikel-ID 473, Seite 1-13  |h Online-Ressource  |w (DE-627)71862713X  |w (DE-600)2662248-8  |w (DE-576)365413666  |x 2075-4426  |7 nnas  |a KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer 
773 1 8 |g volume:11  |g year:2021  |g number:6  |g elocationid:473  |g pages:1-13  |g extent:13  |a KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer 
856 4 0 |u https://doi.org/10.3390/jpm11060473  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2075-4426/11/6/473  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20211005 
993 |a Article 
994 |a 2021 
998 |g 128501014  |a Erben, Philipp  |m 128501014:Erben, Philipp  |d 60000  |d 63100  |e 60000PE128501014  |e 63100PE128501014  |k 0/60000/  |k 1/60000/63100/  |p 5 
998 |g 1049742745  |a Kriegmair, Maximilian  |m 1049742745:Kriegmair, Maximilian  |d 60000  |d 63100  |e 60000PK1049742745  |e 63100PK1049742745  |k 0/60000/  |k 1/60000/63100/  |p 4 
999 |a KXP-PPN1772422061  |e 398452515X 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title_sort":"KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer","title":"KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer"}],"recId":"1772422061","origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"26 May 2021"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 05.10.2021"],"relHost":[{"pubHistory":["1.2011 -"],"language":["eng"],"part":{"volume":"11","year":"2021","text":"11(2021), 6, Artikel-ID 473, Seite 1-13","pages":"1-13","extent":"13","issue":"6"},"title":[{"title_sort":"Journal of Personalized Medicine","subtitle":"open access journal","title":"Journal of Personalized Medicine"}],"recId":"71862713X","origin":[{"publisher":"MDPI","dateIssuedDisp":"2011-","dateIssuedKey":"2011","publisherPlace":"Basel"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 18.06.20"],"id":{"zdb":["2662248-8"],"issn":["2075-4426"],"eki":["71862713X"]},"disp":"KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancerJournal of Personalized Medicine","physDesc":[{"extent":"Online-Ressource"}]}],"id":{"doi":["10.3390/jpm11060473"],"eki":["1772422061"]},"physDesc":[{"extent":"13 S."}],"name":{"displayForm":["Hendrik Jütte, Moritz Reike, Ralph M. Wirtz, Maximilian Kriegmair, Philipp Erben, Karl Tully, Veronika Weyerer, Markus Eckstein, Arndt Hartmann, Sebastian Eidt, Felix Wezel, Christian Bolenz, Andrea Tannapfel, Joachim Noldus and Florian Roghmann"]},"person":[{"family":"Jütte","display":"Jütte, Hendrik Jan","given":"Hendrik Jan","role":"aut"},{"display":"Reike, Moritz","given":"Moritz","role":"aut","family":"Reike"},{"family":"Wirtz","role":"aut","given":"Ralph M.","display":"Wirtz, Ralph M."},{"family":"Kriegmair","display":"Kriegmair, Maximilian","given":"Maximilian","role":"aut"},{"family":"Erben","display":"Erben, Philipp","role":"aut","given":"Philipp"},{"role":"aut","given":"Karl","display":"Tully, Karl","family":"Tully"},{"family":"Weyerer","display":"Weyerer, Veronika","role":"aut","given":"Veronika"},{"family":"Eckstein","display":"Eckstein, Markus","role":"aut","given":"Markus"},{"display":"Hartmann, Arndt","role":"aut","given":"Arndt","family":"Hartmann"},{"given":"Sebastian","role":"aut","display":"Eidt, Sebastian","family":"Eidt"},{"family":"Wezel","role":"aut","given":"Felix","display":"Wezel, Felix"},{"family":"Bolenz","display":"Bolenz, Christian","role":"aut","given":"Christian"},{"family":"Tannapfel","given":"Andrea","role":"aut","display":"Tannapfel, Andrea"},{"family":"Noldus","given":"Joachim","role":"aut","display":"Noldus, Joachim"},{"family":"Roghmann","display":"Roghmann, Florian","role":"aut","given":"Florian"}]} 
SRT |a JUETTEHENDKRT20KRT5E2620